-
Local innovative pharmaceutical companies are strengthening their "self-hematopoietic" capabilities, and another pharmaceutical company has reached a license out transaction
Time of Update: 2022-08-15
Judging from the license-out projects of domestic innovative drugs exceeding US$1 billion in recent years, for example, in early 2021, BeiGene announced that it had reached a cooperation and licensing agreement with Novartis on the development, production and commercialization of tislelizumab in multiple countries.
-
Aiming at the broad domestic pharmaceutical equipment market, the construction of new projects for pharmaceutical machine companies is in full swing
Time of Update: 2022-08-15
. Taking Chutian Technology as an example, it announced on August 2 that the company intends to jointly fund the establishment of a company in Ningxiang City, Changsha, Hunan Province to provide medical equipment, medical equipment, mechanical engineering and other related industries with a team of experts in the precision manufacturing industry.
-
The centralized procurement of low-value consumables continues to expand. Which categories are the first to achieve nationwide price reductions?
Time of Update: 2022-08-15
Category 7 consumables, bidding and negotiating procurement with volume On June 21, 2022, the Shanxi South Film Alliance released the "Announcement on the 6th round of bidding and negotiation of procurement of medical consumables in the four-city alliance of Yuncheng, Linfen, Changzhi and Jincheng" .
-
The eve of bid opening!
Time of Update: 2022-08-15
The criteria for determining the companies to be selected in this centralized procurement continue the previous principle of price reduction (see Scenario 1 below), but the specific rules are more detailed (see Scenario 2 below) .
-
The two pharmaceutical business sector companies achieved revenue exceeding 100 billion yuan
Time of Update: 2022-08-15
According to the 2021 performance report data released by Shanghai Pharmaceuticals, the company's operating income in 2021 will increase by 12.
According to the 2021 performance report data released by Shanghai Pharmaceuticals, the company's operating income in 2021 will increase by 12.
-
Starting in August, this pharmaceutical company ushered in more than 150 institutional research
Time of Update: 2022-08-15
, Sunshine private equity institutions Among them, Jiudian Pharmaceutical released a record form of investor relations activities on August 1, stating that the company accepted 151 institutional research on August 1, 2022.
-
【Shichen】Enter a high-tech enterprise——Topchain Pharma/Topchain Pharma
Time of Update: 2022-08-15
sample application Microcrystalline cellulose, pellet core, co-processing Scan the code to receive samples Dongchen Pharmaceutical The company integrates research and development, production and sales, with the goal of building an internationally renowned and domestic leading modern high-tech enterprise and service provider.
-
High-tech regular bacteria Yieryou has a new action! Liquid probiotics are about to shock the market
Time of Update: 2022-08-15
At that time, Zhongweiyuan Biotechnology will Yieryou active probiotic drink was released It is understood that on May 18, the 2022 China Probiotics Industry Development Summit Forum, hosted by the People's Government of Longzihu District, Bengbu, Anhui, and the China Health Care Association, and co-organized by Zhongweiyuan Biotechnology, will be held at the Bengbu Radio and Television Station, Anhui Province.
-
Antibody research and development change?
Time of Update: 2022-08-15
Big Molecule Popular Tracks Platform differentiation stimulates potential Whether it is from the technical iteration path of overseas pharmaceutical companies or the development process of domestic macromolecular drugs in China, the most common summary of antibody drug research and development is undoubtedly "monoantibodies look at the target, non-mabone look at the platform", which is also highly summarized The important value of the innovative technology platform in the upgrading of antibody R&D technology .
-
The consistency evaluation of 513 varieties of generic drugs has passed the review, and since July, there have been many products from pharmaceutical companies.
Time of Update: 2022-08-15
. Recently, Yuan Lin, director of the Drug Supervision Department of the State Food and Drug Administration, introduced that as of now, the State Food and Drug Administration has reviewed and approved 513 varieties of generic drug consistency evaluation applications involving 2,555 product specifications, and the quality of the listed generic drugs has been continuously improved.
-
The Center for Drug Evaluation of the State Food and Drug Administration released the "Annual Report on the Progress of New Drug Registration Clinical Trials in China (2021)"
Time of Update: 2022-08-15
pdf In order to fully grasp the progress of clinical trials for new drug registration in China, use information technology to improve drug supervision capabilities, disclose clinical trial progress information in a timely manner, and provide reference for new drug research and development, resource allocation, and drug review and approval, the Center for Drug Evaluation is based on the registration and approval of drug clinical trials.
-
Pharmaceutical companies have intensively ushered in high-level personnel changes, and the positions of general managers/deputy general managers have changed frequently
Time of Update: 2022-08-15
. The pharmaceutical company has changed 9 times in the past year, and Renhe Pharmaceutical issued an announcement at noon on July 26, saying that the company's board of directors received the company's director and general manager, Mr. Zhang Wei, and deputy general manager, Mr. Wang Zhen, on July 26, 2022.
-
On the same day, there were major changes in the executives of many pharmaceutical companies
Time of Update: 2022-08-15
For example, AstraZeneca also issued an internal announcement in April this year: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons .
-
Biotech's dilemma?
Time of Update: 2022-08-15
In the past 5 trading days, the stock price of Tianjing Bio has been falling continuously, and the phase II clinical trial (CP-MGA271-06) of its partner MacroGenics' core product B7-H3 monoclonal ant
-
China's State Food and Drug Administration: Promoting the digital transformation and upgrading of drug supervision
Time of Update: 2022-08-15
The State Drug Administration of China recently issued the "14th Five-Year Plan for Drug Regulatory Network Security and Informatization Construction" . When introducing various key tasks, the "Plann
-
Sharing, Q&A, and lucky draw are three linkages!
Time of Update: 2022-08-15
[Pharmaceutical Network Conference Forum] After waiting for more than half a month, "Green Good Technology Enters the Chemical Industry Park Online Roadshow - Embrace the Online, Have More Exchanges" and finally meet you on time on August 5, 2022!
-
Financing in the field of innovative drugs is active, and it has become a general trend for pharmaceutical companies to accelerate the development of new drugs
Time of Update: 2022-08-15
Since the beginning of this year, the pharmaceutical industry has been setting off a wave of financing; for example, recently, a number of pharmaceutical companies have announced that they will raise or have completed hundreds of millions of financing, which will be used for new drug research and development .
-
The Chinese herbal medicine industry is accelerating its development towards standardization and standardization, and a large number of pharmaceutical companies will usher in good news
Time of Update: 2022-08-15
Driven by national policies, various localities are paying more and more attention to the development of the Chinese herbal medicine industry, and they have begun to accelerate the release of development plans and measures related to the cultivation and processing of Chinese herbal medicines to promote the standardized and large-scale cultivation of Chinese herbal medicines and improve the quality of Chinese herbal medicines .
-
Over 500 domestic drugs have been approved, and these two drugs account for the majority
Time of Update: 2022-08-15
. It is worth noting that obtaining new approvals for pharmaceutical companies can improve market competitiveness.
Therefore, many companies are currently accelerating the acquisition of new approvals through various forms It is worth noting that obtaining new approvals for pharmaceutical companies can improve market competitiveness.
-
Centralized procurement of proprietary Chinese medicines is overwhelming!
Time of Update: 2022-08-15
Under the new situation of increasing the speed of centralized procurement and expanding coverage, in order to maintain their clinical dominant position, large varieties of Chinese patent medicines need to improve evidence-based basis based on clinical treatment value, or develop new drug indications and find new drug use scenarios.
